BiliStop mobile app

BiliStop is an evidence-based mobile application that provides a scenario-specific assessment of the risks of rebound phototherapy for infants born more than 35 weeks of gestational age within 72 hours of first phototherapy termination.

Worldwide, hyperbilirubinemia is a leading cause of a baby dying or suffering from neuro-development disabilities. Newborn phototherapy is an effective treatment, but like every medical treatment, has potential unintended side effects. Phototherapy in neonates has been associated with pediatric cancer and seizures. A recent large study found that more than 1/3 of infants may have been able to go home a day earlier with [less than] 4% risk of rebound jaundice.

According to the 2022 American Academy of Pediatrics clinical practice guidelines revision on the management of hyperbilirubinemia, “the decision to discontinue phototherapy is based on balancing the desire to minimize exposure to phototherapy and separation of mothers and infants against the desire to avoid a rebound in TSB following phototherapy. ”

BiliStop helps providers determine this balance.

BiliStop is based on the 2017 paper A Clinical Prediction Rule for Rebound Hyperbilirubinemia Following Inpatient Phototherapy, published in Pediatrics by Chang, et al . Newborn care providers respond to prompts about their patient’s clinical data. One of the data is the AAP threshold for phototherapy for the specific patient in his/her specific clinical scenario. This number can be calculated using the BiliTool TM free website. BiliStop opens up this website for the user within the app but does not calculate this number for the user.

BiliStop has been studied in IRB-approved clinical research, the results of which show that BiliStop is not only more accurate than hand calculation/calculation using a regular calculator but also provides significantly better end-user satisfaction. The work was presented at the American Federation for Medical Research in 02/2020 and recently published in Neonatology Today in 08/2020.

The advantage of Bilistop:

• the number needed to treat (NNT) is 2.2 for 1 infant to benefit from its use.

• significantly higher user satisfaction than hand calculation

• time-saving

• most evidence-based phototherapy termination decision tool
  

Utilizing BiliStop saves time on clinical rounds and saves lives and healthcare dollars with its accuracy in assisting clinical decision-making in neonatal jaundice.

BiliStop is intended for use by neonatologists, pediatricians, family medicine providers, neonatal nurse practitioners, medical residents, and medical students who treat newborn infants in the hospital and in outpatient settings. BiliStop should be used only as a reference aid and educational tool. The information required to put in this app are values commonly used in medical practice, and the result generated should not be used as a substitute for the clinician's clinical judgment. Please contact the developers if errors are found.

The developers shall not be held liable for any damages resulting from the use of this app. The developers reserve the right to modify or discontinue BiliStop without notice.